SarahBGoldbergMD

Oncology • New Haven, CT

Assistant Professor of Medicine, Medical Oncology

Join to view full profile

Dr. Goldberg is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Goldberg's full profile

Already have an account?

Office
333 Cedar St
Fmp130
New Haven, CT 06520
Phone+1 203-785-7564

Fax+1 203-785-3788

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2009 - 2012
Massachusetts General HospitalResidency, Internal Medicine, 2006 - 2009
Icahn School of Medicine at Mount SinaiClass of 2006

Certifications & Licensure

CT State Medical License 2012 - 2025
MA State Medical License 2008 - 2013
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

MK-3475 in Melanoma and NSCLC Patients With Brain Metastases Start of enrollment: 2014 Mar 01
Completed
Phase 2
S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer Start of enrollment: 2015 May 07
Active, not recruiting
Phase 2, Phase 3
Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC Start of enrollment: 2022 Feb 10
Terminated
Phase 2

Publications & Presentations

PubMed

129 citations
A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers
Scott N. Gettinger, June-Seek Choi, Nikita Mani, Miguel F. Sanmamed, Ila Datar
Nature Communications. 2018-08-10
450 citations
Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer
Scott N. Gettinger, Jungmin Choi, Katherine Hastings, Anna Truini, Ila Datar
Cancer Discovery. 2017-12-01
8 citations
Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort St...
Amin H Nassar, So Yeon Kim, Jacqueline V Aredo, Jamie Feng, Frances Shepherd
Journal of Thoracic Oncology. 2024-06-01

Journal Articles

Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer
Guoping Cai, Sarah B Goldberg, Scott Gettinger, Anne Chiang, Roy S Herbst, David L Rimm, Kurt Schalper, Richard Lifton, Clinical Cancer Research

Lectures

Optimizing the Use of Immunotherapy
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Durability of brain metastasis response and overall survival in patients with non-small cell lung cancer (NSCLC) treated with pembrolizumab.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

Experts in TrainingJanuary 20th, 2021
Better Treatments for Lung Cancer That Spreads to the BrainNovember 18th, 2020
Dr. Goldberg Discusses the Diagnosis of Mesothelioma (Short Video)April 5th, 2019
Join now to see all